Euroasia R&D is the research chemicals division of the Euroasia Group of Companies, a multi-disciplinary enterprise with over a decade of operations across pharmaceutical raw materials, active pharmaceutical ingredients (APIs), and life sciences supply.

We were founded on a single observation: that research scientists spending weeks chasing reliable compound supply are scientists not doing science. Our mandate is to eliminate that bottleneck — providing the oncology research community with consistent, analytically documented compounds that go directly from our shipment to the assay.

Our team combines expertise across medicinal chemistry, analytical science, regulatory affairs, and pharmaceutical logistics. We work closely with synthesis partners, contract research organisations, and independent QC laboratories across India, Europe, and East Asia to maintain both the breadth of our catalog and the integrity of every compound within it.

What We Supply

Our catalog focuses exclusively on oncology-relevant small molecules and biologics — the compounds that matter most to cancer biology researchers today:

• Approved targeted inhibitors — PARP, KRAS, EGFR, HER2, BRAF, MEK, CDK4/6, PI3K/AKT/mTOR, ALK, FGFR, VEGFR, BTK, JAK, FLT3, and more
• Emerging pipeline agents — first-in-class compounds from 2024–2026 FDA/EMA approvals, including KRAS G12D inhibitors, PROTAC degraders, and bispecific antibody research standards
• Haematological malignancy agents — IDH1/2, menin-KMT2A, BCR-ABL1, PLK1, and aurora kinase inhibitors
• Immune oncology tools — PD-1/PD-L1 reference antibodies, IL-6R antagonists, TNF-alpha inhibitors, and T-cell engager research standards
• DNA damage response compounds — WEE1, ATR, DNA-PKcs, and FAK inhibitors

Every compound is available with full analytical documentation, from milligram research scale up to gram-level programme quantities.

Synthesis & Sourcing Capabilities

Euroasia R&D operates a dual-track supply model designed to give researchers both speed and assurance.

Custom Synthesis: Through our network of validated synthesis partners, we offer custom synthesis of compounds outside our standard catalog. Our medicinal chemistry consultants work with your specifications — target molecule, salt form, stereochemical requirements, and quantity — and deliver a synthesis proposal within 48 hours. Typical lead times range from 3 to 8 weeks depending on structural complexity, with full analytical documentation at handover.

Compound Sourcing: For catalog compounds and widely referenced research standards, we maintain pre-qualified sourcing agreements with GMP-capable manufacturers in India, China, and Europe. Each supplier is periodically audited against our vendor qualification criteria covering synthesis route documentation, analytical capability, and chain-of-custody traceability.

Scale & Flexibility: We routinely fulfil orders from 1 mg exploratory samples to multi-gram programme quantities. For institutions requiring standing supply, Euroasia R&D offers scheduled delivery contracts to ensure uninterrupted compound availability.

Quality Control Process

Every compound dispatched by Euroasia R&D passes through a mandatory multi-stage analytical QC workflow. We do not release any batch based solely on supplier certificates.

1. Identity Confirmation — NMR & MS: Proton ¹H-NMR confirms structural identity against reference spectra. High-resolution mass spectrometry (HRMS) confirms the molecular formula and rules out structural isomers. For complex molecules, LC-MS/MS fragmentation profiling is applied.

2. Purity Assessment — HPLC: Purity is quantified by reverse-phase HPLC (UV detection at 214 nm and 254 nm). Our standard threshold is ≥99% purity for small molecules. Batches falling below this are rejected and re-purified or re-sourced. The chromatogram and purity figure are included in the Certificate of Analysis (CoA) with every order.

3. Solubility & Stability Testing: Representative samples from each batch undergo solubility screening in DMSO and aqueous buffers. Stability under recommended storage conditions (typically −20°C, desiccated, light-protected) is monitored and re-tested at defined intervals to confirm catalog stock remains within specification.

4. Certificate of Analysis (CoA): Every shipment is accompanied by a batch-specific CoA documenting compound name, CAS number, catalog number, lot number, appearance, molecular weight, molecular formula, purity (HPLC), and storage conditions.

5. Packaging & Cold-Chain Logistics: Compounds are packaged under inert atmosphere where required, sealed in amber glass vials with PTFE-lined caps, and labelled in accordance with GHS hazard classification. Temperature-sensitive shipments are dispatched with appropriate cold-pack insulation validated for the destination transit time.

Our Commitment

Cancer research is time-critical. A failed assay caused by a substandard compound, a delayed shipment, or a missing CoA costs weeks of scientific effort. Euroasia R&D exists to make sure that never happens on our account.

We are a team of scientists and supply chain professionals who take our role in the research ecosystem seriously. Whether you are running a target validation screen, building a mechanistic model, or characterising a resistance pathway, you can rely on Euroasia R&D compounds to perform as documented — every time.

For custom compound requests, bulk quotations, or technical enquiries, contact us at karanchokhani@euroasiarnd.com or cmd@euroasiasgroup.com.